{"url":"https://newsforagent.com/news/2026-11-12/clarity-pharmaceuticals-fda-breakthrough-prostate-imaging","markdown_url":"https://newsforagent.com/news/2026-11-12/clarity-pharmaceuticals-fda-breakthrough-prostate-imaging.md","title":"Clarity Pharmaceuticals Wins FDA Breakthrough Status for Prostate Imaging","headline":"Clarity Pharmaceuticals Secures First PSMA PET Breakthrough Therapy Designation for Cu-64 SAR-bisPSMA","description":"Clarity Pharmaceuticals received FDA Breakthrough Therapy designation for Cu-64 SAR-bisPSMA prostate cancer imaging.","section":"Regulation & Approvals","published_at":"2026-11-12T00:52:04+00:00","modified_at":"2026-11-12T00:52:04+00:00","author":"News Desk","key_takeaways":["Clarity Pharmaceuticals received FDA Breakthrough Therapy designation for Cu-64 SAR-bisPSMA imaging in suspected recurrent prostate cancer on November 12, 2026.","The designation is the first of its kind in PSMA PET imaging and draws on Co-PSMA and COBRA trial data.","Phase III AMPLIFY and CLARIFY have completed recruitment, with topline results expected in the first half of 2027."],"companies":[{"name":"Clarity Pharmaceuticals","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000aw7/clarity-pharmaceuticals","website":"http://www.claritypharmaceuticals.com"}],"source":{"publisher":"The future of trading","title":"Clarity Pharmaceuticals wins FDA breakthrough designation for Cu-64 SAR-bisPSMA prostate cancer imaging agent","url":"https://capital.com/en-int/news/clarity-pharmaceuticals-wins-fda-breakthrough-designation-for-cu-64-sar-bispsma-prostate"},"other_sources":[],"tags":["Regulation & Approvals","Clarity Pharmaceuticals"],"body_markdown":"Clarity Pharmaceuticals received FDA Breakthrough Therapy designation for Cu-64 SAR-bisPSMA imaging in suspected recurrent prostate cancer on November 12, 2026, [The future of trading](https://capital.com/en-int/news/clarity-pharmaceuticals-wins-fda-breakthrough-designation-for-cu-64-sar-bispsma-prostate) reported. The designation is the first of its kind in PSMA PET imaging, according to the report.\n\n## What the FDA Designation Covers\n\nThe Breakthrough Therapy designation provides intensive FDA guidance intended to speed development and review of the imaging agent. Co-PSMA and COBRA trial data, supported by real-world evidence, indicated better detection of recurrent prostate cancer than standard-of-care PSMA PET imaging, the report said. Co-PSMA results were already presented at European urology and nuclear medicine congresses, supporting the designation.\n\n[Clarity Pharmaceuticals](https://akta.pro/company-profiles/0000aw7/clarity-pharmaceuticals) is a Sydney-based radiopharmaceutical company founded in 2010 that develops copper-based diagnostics and therapies for cancer, according to akta.pro [company records](https://akta.pro/company-data). The company's registrational Phase III trials AMPLIFY and CLARIFY have completed recruitment, with topline results expected in the first half of 2027 to support FDA applications.\n\n## Clarity's Manufacturing and Trial Scale\n\nClarity's supply and manufacturing strategy is positioned to provide over 2 million doses of copper-64 per year at base capacity for commercial launch, more than twice the total addressable market for PSMA PET, the same records show. The company signed a commercial manufacturing agreement with Nucleus RadioPharma in April 2026 covering production at Rochester, Minnesota, at 50,000 doses per year and a planned Spring House, Pennsylvania facility at 600,000 doses per year in 2028. In March 2026 it signed a large-scale copper-64 supply agreement with Theragenics at a 134,000 sq ft, 14-cyclotron facility near Atlanta, Georgia, enabling about 2,000 patient doses per day per cyclotron. Approximately 600 patients with prostate cancer had been imaged with 64Cu-SAR-bisPSMA as of March 2026, with over 350 imaged in the prior year across clinical trials.\n\n## Earlier Clarity Trial Milestones\n\nClarity dosed its target of 383 participants in the Phase III CLARIFY prostate cancer imaging trial in October 2026, The future of trading reported. The trial evaluates 64Cu-SAR-bisPSMA's sensitivity and specificity for detecting pelvic lymph node cancer, with histopathology as reference. In August 2026, Yahoo reported that Clarity announced preliminary results from the SECuRE trial evaluating 67Cu-SAR-bisPSMA for prostate cancer treatment, at the 8 GBq dose level with two additional complete responses.\n\n## When Clarity Expects Phase III Data\n\nTopline results from the Phase III AMPLIFY and CLARIFY trials are expected in the first half of 2027 to support FDA applications, the report said.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}